Company intelligence / Profile preview
HealthBiome
Daejeon, South Koreaen.healthbiome.co.kr ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has confirmed the effectiveness of Akkermansia muciniphila (HB03) as an anti-cancer drug candidate in preclinical trials in September 2020. HB03 has shown excellent anticancer activity in various types of cancers including colorectal, lung, pancreatic, melanoma, glioblastoma, and sarcoma[5].
- Therapeutic areas
- OncologyMetabolic DisordersEndocrinologyImmunologyPsychiatryNeurology
- Modalities
- Microbiome-based therapeuticsStrict anaerobic gut microbiome
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Korea Research Institute of Bioscience and Biotechnology (KRIBB)
Beyond the preview
Go deeper on HealthBiome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HealthBiome.